Healthcare | April 28, 2026
Rheumatology Awareness Walkathon 2026 spotlights arthritis and autoimmune care
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
The deal signals a clear push to expand access to care in underserved regions
Subscribe To Our Newsletter & Stay Updated
